Hoppa till innehållet
Zinzino group revenue increased with a total of 14 % in Q1 compared with the previous year.
The revenue in March for Zinzino's sales markets increased by 9% and amounted to SEK 148.9 (136.2) million. Faun Pharma's external sales decreased with 1 % and amounted to SEK 9.7 (9.8) million. Overall, the Group increased revenues by 9% to SEK 158.6 (146.0) million compared with the previous year.
The group revenue increased with 14 % for Q1 2024 compared with the first quarter last year and amounted to SEK 450.4 (393.7) million.
Revenues were distributed as follows:
Regions, 24-mar 23-mar Change Q1 2024 Q1 2023 Change
mSEK
The 22.6 26.8 -16% 66.8 73.6 -9%
Nordics
Central 41.7 35.5 17% 117.8 90.9 30%
Europe
East 32.1 34.6 -7% 93.3 92.5 1%
Europe
South & 25.7 18.7 37% 70.7 49,0 44%
West
Europe
The 7.9 7.7 3% 23.6 21.1 12%
Baltics
North 12.7 7,0 81% 34.7 19.6 77%
America
Asia 5,0 4.5 11% 12.7 15.6 -19%
-Pacific
Africa 1.2 1.4 -14% 3.3 3.8 -13%
Zinzino 148.9 136.2 9% 422.9 366.1 16%
Faun 9.7 9.8 -1% 27.5 27.6 0%
Pharma
Zinzino 158.6 146.0 9% 450.4 393.7 14%
Group
Countries in regions:
-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Turkey
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA, Mexico
-Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
-Africa: South Africa
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com
Pictures for publication free of charge:
Certified Adviser: Carnegie Investment Bank AB (publ)